Notably, antibody-directed inhibition of Slamf4 receptor reversed lytC_22-induced MDSC activation, inferring the role of lytC_22–Slamf4 in MDSC activation following their recruitment to CRC tumours. The gene discussed is CD244; the disease is neoplasm.